John Symeonides, MD
Family Medicine · Palm Coast, FLNPI 1063600310
Payments from drug & device makers
Across 222 payments — averaging $33.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$796
- Alkermes, Inc.$621
- Indivior Inc.$551
- Bayer$529
- Vanda Pharmaceuticals Inc.$393
- plus $3K from 35 others
Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$125
What the payments were for
- Food & beverage$7,366100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 36 | $1,212 |
| Novo Nordisk | 16 | $796 |
| Alkermes, Inc. | 19 | $621 |
| Indivior Inc. | 24 | $551 |
| Bayer | 12 | $529 |
| Vanda Pharmaceuticals Inc. | 14 | $393 |
| Pear Therapeutics (US), Inc. | 8 | $380 |
| AstraZeneca | 8 | $249 |
| Watermark Medical, Inc. | 1 | $217 |
| Amgen | 4 | $196 |
| Braeburn Inc. | 5 | $190 |
| Jazz Pharmaceuticals Inc. | 3 | $165 |
| Lilly USA, LLC | 4 | $153 |
| Johnson & Johnson | 1 | $150 |
| Otsuka America Pharmaceutical, Inc. | 7 | $147 |
| Boehringer Ingelheim | 4 | $144 |
| Mylan Specialty L.p. | 1 | $125 |
| Novartis | 8 | $114 |
| Merck | 6 | $103 |
| Orexo US, Inc. | 6 | $103 |
| Harmony Biosciences LLC | 1 | $96 |
| Relievant Medsystems, Inc. | 1 | $86 |
| Exact Sciences | 3 | $84 |
| Sunovion Pharmaceuticals Inc. | 4 | $62 |
| USWM, LLC | 4 | $61 |
| Titan Pharmaceuticals, Inc. | 3 | $60 |
| GSK | 3 | $55 |
| Scilex Pharmaceuticals Inc. | 1 | $47 |
| MDD US Operations, LLC | 2 | $41 |
| Itamar Medical Inc | 1 | $33 |
| Shire North American Group Inc | 2 | $32 |
| Radius Health, Inc. | 1 | $28 |
| Astellas Pharma US Inc | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Agios Pharmaceuticals, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Vivus LLC | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Organogenesis Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,383 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 75 | $45,143 |
| OzempicSemaglutide | 15 | $23,883 |
| MyrbetriqMirabegron | 37 | $21,327 |
| XareltoRivaroxaban | 30 | $20,827 |
| MounjaroTirzepatide | 15 | $16,562 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 78 | $15,392 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 207 | $13,676 |
| JardianceEmpagliflozin | 16 | $13,223 |
| EntrestoSacubitril/Valsartan | 23 | $10,497 |
| JanuviaSitagliptin Phosphate | 18 | $9,920 |
| GemtesaVibegron | 19 | $8,389 |
| LinzessLinaclotide | 13 | $7,211 |
| Levothyroxine Sodium | 285 | $3,642 |
| Lacosamide | 12 | $3,598 |
| Gabapentin | 133 | $3,320 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $796 | $23,88315 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $21,32737 claims |
| Johnson & JohnsonXarelto | $150 | $20,82730 claims |
| Lilly USA, LLCMounjaro | $153 | $16,56215 claims |
| Orexo US, Inc.Zubsolv | $103 | $15,39278 claims |
| Boehringer IngelheimJardiance | $144 | $13,22316 claims |
| NovartisEntresto | $114 | $10,49723 claims |
| MerckJanuvia | $103 | $9,92018 claims |
| AbbVieLinzess | $1,212 | $7,21113 claims |
| Indivior Inc.Suboxone | $551 | $3,16811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Palm Coast
- Sharrell CooperPalm Coast$16.9M
- Chiamaka IhemePalm Coast$10.4M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.